-
EP3984989
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3984989
| EP3984989 - IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND USE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 18.03.2022 Database last updated on 13.07.2024 | |
| Former | The international publication has been made Status updated on 21.02.2022 | ||
| Former | unknown Status updated on 24.12.2021 | Most recent event Tooltip | 31.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. Building 10 Nanjing Life Science Techtown No. 568 Longmian Avenue Jiangning District Nanjing, Jiangsu 211100 / CN | [2022/16] | Inventor(s) | 01 /
YE, Hai Nanjing Jiangsu 211100 / CN | 02 /
MIN, Tao Nanjing Jiangsu 211100 / CN | 03 /
LV, Tian Nanjing Jiangsu 211100 / CN | 04 /
ZHOU, Wenliang Nanjing Jiangsu 211100 / CN | 05 /
CHEN, Xingran Nanjing Jiangsu 211100 / CN | 06 /
FENG, Yunqing Nanjing Jiangsu 211100 / CN | 07 /
MO, Meiling Nanjing Jiangsu 211100 / CN | 08 /
WANG, Jialin Nanjing Jiangsu 211100 / CN | [2022/16] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [2022/16] | Application number, filing date | 21824460.6 | 28.06.2021 | [2022/16] | WO2021CN102752 | Priority number, date | CN202010815093 | 13.08.2020 Original published format: CN202010815093 | [2022/16] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022033202 | Date: | 17.02.2022 | Language: | ZH | [2022/07] | Type: | A1 Application with search report | No.: | EP3984989 | Date: | 20.04.2022 | Language: | EN | [2022/16] | Search report(s) | International search report - published on: | CN | 17.02.2022 | (Supplementary) European search report - dispatched on: | EP | 25.10.2023 | Classification | IPC: | C07C69/96, C07C68/06, A61P19/02, A61P29/00, A61P25/04, A61K31/265, A61K31/192 | [2023/47] | CPC: |
C07C69/96 (EP,KR);
A61K31/265 (KR,US);
A61K31/192 (US);
A61K9/0019 (US);
A61K9/06 (US);
A61P19/02 (EP,KR);
A61P25/04 (EP,KR);
A61P29/00 (EP,KR);
C07C68/02 (KR);
| C-Set: |
C07C68/06, C07C69/96 (EP)
|
| Former IPC [2022/16] | C07C69/96, C07C68/06, C07C68/00, A61P19/02, A61P29/00, A61P25/04, A61K31/265, A61K31/192 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/16] | Title | German: | IBUPROFENESTER-PRODRUG, PHARMAZEUTISCHE ZUSAMMENSETZUNG SOWIE HERSTELLUNGSVERFAHREN UND VERWENDUNG | [2022/16] | English: | IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND USE | [2022/16] | French: | PROMÉDICAMENT D'ESTER D'IBUPROFÈNE, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉ DE PRÉPARATION ET D'UTILISATION | [2022/16] | Entry into regional phase | 24.12.2021 | Translation filed | 24.12.2021 | National basic fee paid | 24.12.2021 | Search fee paid | 24.12.2021 | Designation fee(s) paid | 24.12.2021 | Examination fee paid | Examination procedure | 24.12.2021 | Examination requested [2022/16] | 10.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 29.03.2023 | Renewal fee patent year 03 | 30.05.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]US4426391 (ALEXANDER JOSE [US], et al); | [XY]EP0112130 (TEVA PHARMA [IL]); | [Y]US5401868 (LUND FRANTZ J [DK]); |